Tofacitinib is under clinical development by Biora Therapeutics and currently in Phase I for Ulcerative Colitis. According to GlobalData, Phase I drugs for Ulcerative Colitis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Tofacitinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tofacitinib (PGN-600) is under development for the treatment of ulcerative colitis. The drug candidate is administered through oral route in the form of liquid. It acts by targeting JAK kinase. It is a drug-device combination being developed based on NaviCap Drug Delivery System (DDS) platform.
Biora Therapeutics overview
Biora Therapeutics, formerly Progenity Inc, is a biotechnology company. It develops oral biotherapeutics to replace injection with needle-free. The company’s pipeline products portfolio includes PGN-600 and PGN-001 liquid formulations delivered with the drug delivery system for the treatment of ulcerative colitis; liquid formulation of anti-TNF-alpha monoclonal antibody delivered with the oral biotherapeutics delivery system for the treatment of autoimmune conditions; and liquid formulation. It develops smart capsule platforms recoverable sampling systems and PIL Dx for GI sampling and diagnostics. The company delivers therapeutics to the site of diseases in the gastrointestinal tract, ulcerative colitis, and inflammatory bowel disease. Biora Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of Tofacitinib’s drug-specific PTSR and LoA scores, buy the report here.